Open AccessInterferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma
Author(s) -
Christopher J. LaRocca,
Amanda O. Salzwedel,
Mizuho Sato-Dahlman,
Margarita V. Romanenko,
Rafael S. Andrade,
Julia Davydova,
Masato Yamamoto
Publication year - 2021
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-021-10382-7
Subject(s) - oncolytic virus , oncolytic adenovirus , virotherapy , cancer research , virology , viral replication , adenoviridae , virus , cytotoxic t cell , interferon , viral vector , medicine , biology , genetic enhancement , in vitro , gene , recombinant dna , biochemistry
Esophageal adenocarcinoma (EAC) has increased in incidence in Western countries, and its poor prognosis necessitates the development of novel therapeutics. We previously reported the potential of conditionally replicative adenoviruses (CRAd) as a novel therapeutic treatment for this disease. To further augment the therapeutic effectiveness of our cyclooxygenase-2 (Cox2) controlled CRAd in EAC, we inserted an interferon alpha (IFN) transgene into the viral genome that is expressed upon viral replication. In this manuscript, we analyze the cytotoxic and oncolytic effects of an IFN-expressing oncolytic adenovirus in EAC and the role of the Cox2 promoter in providing for selective replication in human tissues.